Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Spark Therapeutics, Inc.    ONCE

SPARK THERAPEUTICS, INC.

(ONCE)
SummaryQuotesNewsRatingsCalendarCompany 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Roche to complete $4.3 billion Spark deal as regulators give all clear

share with twitter share with LinkedIn share with facebook
share via e-mail
12/17/2019 | 03:56am EST
FILE PHOTO: Swiss drugmaker Roche's logo is seen at their headquarters in Basel, Switzerland

Swiss drugmaker Roche plans to complete its $4.3 billion takeover of gene therapy specialist Spark Therapeutics on Tuesday after U.S. and British authorities ruled the deal would not hurt competition in hemophilia A treatment.

The Federal Trade Commission (FTC) and Britain's Competition and Markets Authority (CMA) approved the deal on Monday without demanding asset sales.

Roche is buying U.S.-based Spark to expand in gene therapy and boost its hemophilia A portfolio, where the Basel-based company's existing drug Hemlibra will surpass $1 billion sales in 2019.

Regulators had feared Roche might sabotage Spark's hemophilia program to benefit Hemlibra, but came to another conclusion.

"The evidence developed during staff's investigation did not indicate that Roche would have the incentive to delay or terminate Spark's developmental effort for its hemophilia A gene therapy," the FTC said after its 5-0 approval vote.

Clearance for Roche to buy Spark helps reduce the chance the Swiss drugmaker will be eclipsed in one of the industry's most dynamic and potentially profitable areas, as it was by Merck and Bristol-Myers Squibb in immune therapies for cancer.

"That's why the market was increasingly worried that the deal announced in February was taking so long," said Michael Nawrath, an analyst at Zuercher Kantonalbank.

The deal follows Novartis $8.7 billion takeover of gene therapy specialist AveXis in 2018.

Beyond hemophilia, Spark is also working on gene therapies for Pompe and Huntington's diseases, among others.

With the deal, Roche agreed to pay more than twice the U.S. company's closing price on Feb. 22. As of Tuesday, Roche held more than 60% of Spark shares.

"Following completion of the merger, Spark will become a wholly owned subsidiary of Roche," Roche said.

LUCRATIVE, COMPETITIVE

Hemophilia A, where sufferers lack a protein needed for blood clotting, has traditionally been one of the most expensive - and for companies, lucrative - treatment areas.

Traditional treatments can in some cases run into millions of dollars annually.

Spark's hemophilia A treatment is up against a crowded pool of gene therapy hopefuls, something the FTC said influenced its decision not to block the deal.

Biomarin Pharmaceutical is seen filing for approval this year, while Sangamo Therapeutics Inc and Pfizer Inc are steadily producing data from studies.

"As the other companies endeavor to bring their gene therapies to market, Roche would have the incentive to accelerate, rather than decelerate, the development of Spark’s gene therapy," the FTC said.

Roche stock eased 0.2% in early trading.

By Diane Bartz and John Miller

Stocks mentioned in the article
ChangeLast1st jan.
BIOMARIN PHARMACEUTICAL INC. -0.23% 89.66 Delayed Quote.6.04%
NOVARTIS -1.32% 94.56 Delayed Quote.3.81%
ROCHE HOLDING AG -1.57% 345.65 Delayed Quote.10.05%
SANGAMO THERAPEUTICS, INC. 0.94% 7.54 Delayed Quote.-10.75%
SPARK THERAPEUTICS, INC. 0.00%End-of-day quote.0.00%
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SPARK THERAPEUTICS, INC.
2019Trouble for Boeing, Netflix expands, Amazon toughens up against Fedex…
2019SPARK THERAPEUTICS, INC. : Termination of a Material Definitive Agreement, Compl..
AQ
2019SPARK THERAPEUTICS : Roche and Spark Therapeutics, Inc. announce closing of inve..
AQ
2019Roche to complete $4.3 billion Spark deal as regulators give all clear
RE
2019Roche to complete $4.3 billion Spark deal as regulators give all clear
RE
2019SPARK THERAPEUTICS : Roche clears UK hurdle in $4.3 billion Spark deal, U.S. rev..
RE
2019EUROPE : European shares dragged down by Tullow Oil and weak China export data
RE
2019ROCHE : Extends Tender Offer for Spark Therapeutics
DJ
2019SPARK THERAPEUTICS : Swiss drugmaker Roche again extends $4.3 billion Spark offe..
RE
2019SPARK THERAPEUTICS : Roche extends offer deadline for Spark Therapeutics again
RE
More news
Chart SPARK THERAPEUTICS, INC.
Duration : Period :
Spark Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Managers
NameTitle
Stephen W. Webster Chief Financial & Accounting Officer
Federico Mingozzi Chief Scientific Officer
Bruce Resnick Director
Sean A. Johnston Director
Joseph W. La Barge Chief Legal Officer
Sector and Competitors
1st jan.Capitalization (M$)
SPARK THERAPEUTICS, INC.0.00%4 375
GILEAD SCIENCES3.12%85 208
VERTEX PHARMACEUTICALS13.17%64 242
REGENERON PHARMACEUTICALS5.90%43 631
WUXI APPTEC CO., LTD.20.39%26 088
GENMAB12.39%15 371